Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant for Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome
2005-002568-27Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiometabolic risk (CMR) and Abdominal adiposity (ABCD) comparing Rimonabant 20 mg once daily with Placebo once daily (2 arms). Primary endpoint: Relative change in visceral fat area at Month 12. Started Aug 2005; status: completed.
02
Drugs
rimonabant
03
Conditions
cardiometabolic risk (CMR)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on 2005-002568-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002568-27.